Potential Role of MEK Inhibition in Treating Patients with Colorectal Cancer
Paul Brittain, S. Gail Eckhardt and Christopher H. Lieu
Affiliation: University of Colorado School of Medicine, Division of Medical Oncology, 12801 E. 17th Avenue, Mail Stop 8117, Research 1 South, Aurora, Colorado 80045-2530.
Keywords: Colorectal Cancer, MAPK Pathway, MEK Inhibitor, Targeted Therapy.
The mitogen-activated protein kinase (MAPK) signaling pathway plays a fundamental role in the carcinogenesis
of colorectal and numerous other neoplasms. The development of targeted agents that inhibit MEK 1 and 2 has created
the potential for downstream blockade of the MAPK pathway. Though MEK inhibition has demonstrated clinically significant
efficacy in several tumor types, therapeutic success has been limited in colorectal cancer (CRC). This review will
describe the current experience with MEK inhibition. It will also highlight ongoing efforts and future directions, including
potential rational combination strategies and the investigation into potential predictive biomarkers of response.
Rights & PermissionsPrintExport